SNS FiRe Conference Names Atrin Pharmaceutical a 2016 Firestarter Company

Strategic News Service (SNS) has selected Atrin Pharmaceutical, Doylestown, PA, as a 2016 FiReStarter company to be featured at the 14th annual Future in Review (FiRe) conference. FiRe 2016 will take place September 27-30, 2016, at the Stein Eriksen Lodge Deer Valley in Park City, Utah.

Described by The Economist as “the best technology conference in the world,” FiRe features global thought leaders in technology and the global economy, including Elon Musk, Craig Venter, Michael Dell, Vint Cerf, Leroy Hood, Elena Polyakova, Mark Hurd, Paul Jacobs, Cory Doctorow, Kamran Elahian, Ken Goldman, Dharmendra Modha, and many others. FiReStarters are selected based on the strength of their potential to bring positive change to the world, and are showcased at the FiRe conference, in panels throughout the event and with ongoing relationships introduced and supported by SNS.

Atrin Pharmaceuticals is a dynamic biopharmaceutical firm focused on the discovery and development of proprietary medications for the treatment of cancer. Using groundbreaking technology developed and licensed in association with the University of Pennsylvania, Atrin’s bioresearch has led to the development of a portfolio of drug candidates with multiple mechanisms of action. Atrin’s lead program is a novel series of first-in-class, water-soluble, orally bioavailable, highly potent small-molecule inhibitors of ATR for clinical application. Its pipeline of unique small molecules allows specific targeting of a broad spectrum of cancers (pancreatic, lung, ovarian, breast, and colon) with much higher efficacy and lower toxicity than conventional chemotherapeutics.

In addition to the ATR inhibitor series, Atrin’s pipeline also contains two development candidates: ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. Atrin’s scientists have also invented the proprietary Atrize™ platform: an innovative phenotypic FACS-based screening that is broadly applicable across R&D and clinical applications, and as an innovative tool for personalized medicine.

We are honored to be named a 2016 FiReStarter, and our commitment and motivation to transforming the way cancers are treated has never been higher. Atrin’s goal is to commercialize oncologic therapeutics capable of tumor regression without the heinous side effects associated with chemotherapy and radiation. Our early in vivo results using patient-derived tumors are remarkably promising, and the data support that our lead compounds work in multiple forms of cancer. We are delighted to be selected and to have this opportunity to share our passion and science with the world,” said Dr. Oren Gilad, CEO of Atrin Pharmaceutical.

As the world moves into a new era of targeted tumor regression, we are pleased to be able to provide a stage for those leading the charge. We are delighted to be able to have Atrin Pharmaceutical with us this year as a FiReStarter company, and we look forward to the terrific patient benefits their science is set to bring into medical practice,” said Mark Anderson, FiRe Chair and CEO of the Strategic News Service.

fire-logoFuture in Review is a gathering of world-class thought leaders, convened each year with the goal of providing the most accurate look forward in technology. FiRe is a world leader in exploring how technology drives the world economy and in using technology to solve major social challenges. These goals have been consistently achieved through FiRe’s collaborations across technology-driven industries and through active support from the global FiRe community.

To register for FiRe 2016, go to